[HTML][HTML] Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non–small-cell lung cancer
SS Ramalingam, ML Maitland, P Frankel… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
SS Ramalingam, ML Maitland, P Frankel, AE Argiris, M Koczywas, B Gitlitz, S Thomas…
Journal of Clinical Oncology, 2010•ncbi.nlm.nih.govPurpose Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by both histone
and nonhistone–mediated mechanisms. It also enhances the anticancer effects of platinum
compounds and taxanes in non–small-cell lung cancer (NSCLC) cell lines. This phase II
randomized, double-blinded, placebo-controlled study evaluated the efficacy of vorinostat in
combination with carboplatin and paclitaxel in patients with advanced-stage NSCLC.
and nonhistone–mediated mechanisms. It also enhances the anticancer effects of platinum
compounds and taxanes in non–small-cell lung cancer (NSCLC) cell lines. This phase II
randomized, double-blinded, placebo-controlled study evaluated the efficacy of vorinostat in
combination with carboplatin and paclitaxel in patients with advanced-stage NSCLC.
Abstract
Purpose
Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by both histone and nonhistone–mediated mechanisms. It also enhances the anticancer effects of platinum compounds and taxanes in non–small-cell lung cancer (NSCLC) cell lines. This phase II randomized, double-blinded, placebo-controlled study evaluated the efficacy of vorinostat in combination with carboplatin and paclitaxel in patients with advanced-stage NSCLC.
ncbi.nlm.nih.gov